Adherium taps top shareholder for US$1.65m lifeline
What's the deal? AdheriumDealroom has a profile for this one. Try Dealroom → (ASX:ADR), a digital respiratory company behind the FDA-cleared Hailie Smartinhaler, has secured a US$1.65 million short-term loan from major shareholder Trudell MedicalDealroom has a profile for this one. Try Dealroom →.
The unsecured facility carries 12% annual interest, capitalised monthly, and falls due on September 30, 2026. Adherium can repay early without penalty or extend month to month.
Why now? The company flagged a need to reshape its capital structure and says outside financing was scarce or too costly.
"We chose to obtain the Loan Facility from Trudell because alternative funding options are limited, uncertain or available only on materially less favourable terms," its board said.
What could go wrong? Leaning on an existing shareholder raises related-party questions. The board, with Trudell-linked director George Baran abstaining, deemed the terms arm's length and comparable to third-party loans, so no shareholder vote is required under the Corporations Act.
Any default triggers immediate repayment. With shares trading at just $0.0020, the company's options remain thin.
The signal: Trudell Medical's willingness to step in as a corporate lender reflects how early-stage digital health players like Adherium increasingly depend on strategic shareholders when public-market capital dries up. For a company still in the early stages of commercialising its FDA-cleared Hailie platform, the backing of a respiratory-focused corporate partner may matter more than the modest sum involved.
Read more: Grafa
Image credit: Generated with Gemini
